HGF
Hepatocyte growth factor
As of the edition of 20 October 2026, HGF (hepatocyte growth factor, UniProt P14210) has 3 drugs tested at it and 6 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14210
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 36
- Disease areas
- Cancer; Digestive system; Lungs and airways; Blood and lymph; Urinary and reproductive; Hormones; Pregnancy and women's health; Ear, nose and throat
- Registered trials of its drugs
- 31
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rilotumumab | Stopped | Phase 3 | none listed |
| Ficlatuzumab | Active | Phase 3 | none listed |
| MP-0250 | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Amgen | Route A |
| Immunitybio | Route A |
| Molecular Partners | Route A |
The other 3 companies at HGF
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HGF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.